肿瘤相关性贫血的诊治进展

张翼鷟; 兰映霞; 王怡

doi:10.13201/j.issn.1004-2806.2022.11.002

肿瘤相关性贫血的诊治进展

- 中山大学肿瘤防治中心儿童肿瘤科，华南肿瘤学国家重点实验室，肿瘤医学协同创新中心(广州，510060)

详细信息

作者简介:
张翼鷟，教授，主任医师，博士研究生导师，博士后合作导师，华南肿瘤学国家重点实验室课题组组长，中山大学肿瘤防治中心学术委员会委员。担任中国抗癌协会血液病转化研究专业委员会候任主任委员，中国临床肿瘤委员会(CSCO)抗淋巴瘤联盟常委，儿童和青少年学组常务副组长等学术任职。从事血液肿瘤、儿童肿瘤等临床及相关转化研究工作，在国内外杂志发表第一或通讯作者论文170余篇，其中SCI论文70余篇。承担国家自然科学基金面上项目3项、国家科技重大专项子课题1项，国际合作项目2项以及其他省部级课题10余项，第一完成人获得中国抗癌协会科技进步二等奖1项

通讯作者: 张翼鷟，E-mail：zhangyzh@sysucc.org.cn

中图分类号: R556

收稿日期: 2022-09-08

刊出日期: 2022-11-01

Advances in diagnosis and treatment of cancer-related anemia

More Information

Corresponding author: , E-mail: zhangyzh@sysucc.org.cn

Received Date: 08 September 2022

Publish Date: 01 November 2022

摘要

- 肿瘤 /
- 贫血 /
- 治疗
- cancer /
- anemia /
- treatment

HTML全文

表 1 CRA分级 g/L

分级	血红蛋白(NCI贫血分级)	血红蛋白(WHO贫血分级)	血红蛋白(中国贫血分级)
0级(正常)	正常值	≥110	正常值
1级(轻度)	100~ < 正常值	95~ < 110	90~ < 正常值
2级(中度)	80~ < 100	80~95	60~ < 90
3级(重度)	65~ < 80	65~ < 80	30~ < 60
4级(极重度)	< 65	< 65	< 30
注：正常值男性为>120 g/L，女性>110 g/L。

下载: 导出CSV

参考文献(25)

[1]	Madeddu C, Gramignano G, Astara G, et al. Pathogenesis and Treatment Options of Cancer Related Anemia: Perspective for a Targeted Mechanism-Based Approach[J]. Front Physiol, 2018, 9: 1294. https://www.frontiersin.org/articles/10.3389/fphys.2018.01294/full
[2]	Birgegård G, Aapro MS, Bokemeyer C, et al. Cancer-related anemia: pathogenesis, prevalence and treatment[J]. Oncology, 2005, 68(Suppl)1: 3-11. https://link.springer.com/article/10.2165/00024669-200504040-00003
[3]	Schwartz RN. Anemia in patients with cancer: incidence, causes, impact, management, and use of treatment guidelines and protocols[J]. Am J Health Syst Pharm, 2007, 64(3 Suppl 2): S5-S13;quiz S28-S30. https://academic.oup.com/ajhp/article-abstract/64/3_Supplement_2/S5/5135201
[4]	Kenar G, Köksoy EB, Vrün Y, et al. Prevalence, etiology and risk factors of anemia in patients with newly diagnosed cancer[J]. Support Care Cancer, 2020, 28(11): 5235-5242. doi: 10.1007/s00520-020-05336-w
[5]	Paitan V, Alcarraz C, Leonardo A, et al. Anemia as a prognostic factor in cancer patients[J]. Rev Peru Med Exp Salud Publica, 2018, 35(2): 250-258. doi: 10.17843/rpmesp.2018.352.3171
[6]	Stauder R, Valent P, Theurl I. Anemia at older age: etiologies, clinical implications, and management[J]. Blood, 2018, 131(5): 505-514. doi: 10.1182/blood-2017-07-746446
[7]	Natalucci V, Virgili E, Calcagnoli F, et al. Cancer Related Anemia: An Integrated Multitarget Approach and Lifestyle Interventions[J]. Nutrients, 2021, 13(2): 482. doi: 10.3390/nu13020482
[8]	中国抗癌协会肿瘤临床化疗专业委员会, 中国抗癌协会肿瘤支持治疗专业委员会. 中国肿瘤化疗相关贫血诊治专家共识(2019年版)[J]. 中国肿瘤临床, 2019, 46(17): 869-875. doi: 10.3969/j.issn.1000-8179.2019.17.919
[9]	Fukushima T, Nakano J, Ishii S, et al. Influence of Hemoglobin Level on Muscle and Physical Functions, Activities of Daily Living, and Quality of Life in Patients With Hematological Malignancies[J]. Integr Cancer Ther, 2019, 18: 1534735419842196.
[10]	Gilreath JA, Rodgers GM. How I treat cancer-associated anemia[J]. Blood, 2020, 136(7): 801-813. doi: 10.1182/blood.2019004017
[11]	Hoque MM, Adnan SD, Karim S, et al. Equilibration and increase of hemoglobin concentration after one unit whole blood transfusion among patients not actively bleeding[J]. J Dhaka Natl Med Coll Hosp, 2014, 23(2): 161-166.
[12]	Iqbal N, Haider K, Sundaram V, et al. Red blood cell transfusion and outcome in cancer[J]. Transfus Apher Sci, 2017, 56(3): 287-290. https://www.sciencedirect.com/science/article/pii/S1473050217300964
[13]	Bohlius J, Bohlke K, Castelli R, et al. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update[J]. Blood Adv, 2019, 3(8): 1197-1210.
[14]	Song AB, Kuter DJ, Al-Samkari H. Characterization of the rate, predictors, and thrombotic complications of thrombocytosis in iron deficiency anemia[J]. Am J Hematol, 2020, Jul 3. doi: 10.1002/ajh.25925.Epubaheadofprint.
[15]	Tonia T, Mettler A, Robert N, et al. Erythropoietin or darbepoetin for patients with cancer[J]. Cochrane Database Syst Rev, 2012, 12: CD003407.
[16]	Li W, Garcia D, Cornell RF, et al. Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies: A Review[J]. JAMA Oncol, 2017, 3(7): 980-988. doi: 10.1001/jamaoncol.2016.3350
[17]	Adams A, Scheckel B, Habsaoui A, et al. Intravenous iron versus oral iron versus no iron with or without erythropoiesis-stimulating agents(ESA)for cancer patients with anaemia: a systematic review and network meta-analysis[J]. Cochrane Database Syst Rev, 2022, 6: CD012633.
[18]	Steensma DP, Sasu BJ, Sloan JA, et al. Serum hepcidin levels predict response to intravenous iron and darbepoetin in chemotherapy-associated anemia[J]. Blood, 2015, 125(23): 3669-3671. https://mayoclinic.pure.elsevier.com/en/publications/serum-hepcidin-levels-predict-response-to-intravenous-iron-and-da
[19]	DeLoughery TG. Safety of Oral and Intravenous Iron[J]. Acta Haematol, 2019, 142(1): 8-12.
[20]	Birgegård G, Henry D, Glaspy J, et al. A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial[J]. Pharmacotherapy, 2016, 36(4): 402-414.
[21]	Noronha V, Joshi A, Patil VM, et al. Phase Ⅲ randomized trial comparing intravenous to oral iron in patients with cancer-related iron deficiency anemia not on erythropoiesis stimulating agents[J]. Asia Pac J Clin Oncol, 2018, 14(2): e129-e137.
[22]	Avni T, Bieber A, Grossman A, et al. The safety of intravenous iron preparations: systematic review and meta-analysis[J]. Mayo Clin Proc, 2015, 90(1): 12-23. https://www.sciencedirect.com/science/article/pii/S0025619614008830
[23]	Buchrits S, Itzhaki O, Avni T, et al. Intravenous Iron Supplementation for the Treatment of Chemotherapy-Induced Anemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials[J]. J Clin Med, 2022, 11(14): 4156. https://www.tandfonline.com/doi/full/10.3109/0284186X.2012.702921
[24]	Macciò A, Madeddu C, Gramignano G, et al. The role of inflammation, iron, and nutritional status in cancer-related anemia: results of a large, prospective, observational study[J]. Haematologica, 2015, 100(1): 124-132.
[25]	Metsios GS, Moe RH, Kitas GD. Exercise and inflammation[J]. Best Pract Res Clin Rheumatol, 2020, 34(2): 101504. https://academic.oup.com/eurheartj/article/27/11/1385/454432